Adrenomedullin

Adrenomedullin
Identifiers
Symbols	ADM ; AM
External IDs	Template:OMIM5 Template:MGI HomoloGene: 873
Gene ontology Molecular function Template:GNF GO Cellular component Template:GNF GO Template:GNF GO Template:GNF GO Biological process Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO Template:GNF GO
RNA expression pattern
More reference expression data
Orthologs
Template:GNF Ortholog box
Species	Human	Mouse
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Location (UCSC)	n/a	n/a
PubMed search	n/a	n/a

WikiDoc Resources for Adrenomedullin
Articles
Most recent articles on Adrenomedullin Most cited articles on Adrenomedullin Review articles on Adrenomedullin Articles on Adrenomedullin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Adrenomedullin Images of Adrenomedullin Photos of Adrenomedullin Podcasts & MP3s on Adrenomedullin Videos on Adrenomedullin
Evidence Based Medicine
Cochrane Collaboration on Adrenomedullin Bandolier on Adrenomedullin TRIP on Adrenomedullin
Clinical Trials
Ongoing Trials on Adrenomedullin at Clinical Trials.gov Trial results on Adrenomedullin Clinical Trials on Adrenomedullin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Adrenomedullin NICE Guidance on Adrenomedullin NHS PRODIGY Guidance FDA on Adrenomedullin CDC on Adrenomedullin
Books
Books on Adrenomedullin
News
Adrenomedullin in the news Be alerted to news on Adrenomedullin News trends on Adrenomedullin
Commentary
Blogs on Adrenomedullin
Definitions
Definitions of Adrenomedullin
Patient Resources / Community
Patient resources on Adrenomedullin Discussion groups on Adrenomedullin Patient Handouts on Adrenomedullin Directions to Hospitals Treating Adrenomedullin Risk calculators and risk factors for Adrenomedullin
Healthcare Provider Resources
Symptoms of Adrenomedullin Causes & Risk Factors for Adrenomedullin Diagnostic studies for Adrenomedullin Treatment of Adrenomedullin
Continuing Medical Education (CME)
CME Programs on Adrenomedullin
International
Adrenomedullin en Espanol Adrenomedullin en Francais
Business
Adrenomedullin in the Marketplace Patents on Adrenomedullin
Experimental / Informatics
List of terms related to Adrenomedullin

Adrenomedullin is a peptide associated with pheochromocytoma. It was discovered in 1993.

Adrenomedullin (AM) is a ubiquitously expressed peptide initially isolated from phaechromyctoma in 1993 (Kitamura et al., 1998). Since its first report, studies examining the effects of adrenomedullin have mushroomed, highlighting its role in a number of diseases. Recently a second peptide AM2 has been recognised, exhibiting similar functions (Fujisawa et al., 2004).

The Adrenomedullin Peptide

The human AM gene is localized to a single locus on Chromosome 11 with 4 exons and 3 introns. The AM gene initially codes for a 185-amino acid precursor peptide [3], that can be differentially excised to form a number of peptides, including an inactive 53-amino acid AM, e PAMP, adrenotensin and AM95-146. Mature human AM is activated to form a 52 amino acid, 6-amino acid ring, that shares moderate structural similarity to the calcitonin family of regulatory peptides (calcitonin, CGRP and amylin). Circulating AM consists of both amidated (mature) and the glycated form (inactive, with the latter comprising the major form (85%) [5]. The measured to have a plasma half-life of 22min, mean clearance rate of 274 mL/kg/min, and apparent volume of distribution of 880+/- 150 mL/kg (Meeran et al., 1997). Mature AM is metabolised via aminopeptidase action.

Receptors of Adrenomedullin

Main article: Adrenomedullin receptor

At present AM is believed to function through through the combination of a few combinations of the calitonin receptor like receptor (CL) and receptor activity-modifying proteins (RAMP) complexes, as well as CGRP receptors. It is worth noting that unlike the classical one ligand-one receptor notion of receptor signalling, the interaction of both CL and RAMP at the membrane, is required for AM to mediate its action. The outcome of AM stimulatation of its receptor is the cellular production of both cyclic AMP (cAMP) and nitric oxide production. Some may find the production of these inside the cell to be at odds, since often they have opposing effects, but as yet, the timing of these effects remains to be studied.

The physiological functions of Adrenomedullin

AM was initially identified as a vasodilator, some have cited this as the most potent endogenous vasodilatory peptide found in the body (Cockcroft et al., 1997). Differences in opinion regarding the ability of AM to relax vascular tone arises from the differences in the model system used (Hamid and Baxter, 2005). Other effects of AM include increasing the tolerance of cells to oxidative stress and hypoxic injury and angiogenesis. AM is seen as a positive influence in diseases such as hypertension, myocardial infarction, chronic obstructive pulmonary disease and other cardiovascular diseases, whereas it can be seen as a negative factor in potentiating the potential of cancerous cells to extend their blood supply and cause cell proliferation.

Further reading

• Cao et al., Regulated Peptide, 113(1-3),109-114. 2003.
• Cockcroft et al., Br J Clin Pharmacol. 1997 Jul;44(1):57-60.
• Fujisawa Y et al., Eur J Pharmacol. Aug 16;497(1):75-80. 2004.
• Hamid SA, Baxter GF, Pharmacol Ther. Feb;105(2):95-112.2005.
• Kitamura et al., Biochem Biophys Res Commum, 244(2), 551-555. 1998.
• Meeran K et al., J Clin Endocrinol Metab. Jan;82(1):95-100. 1997

External links

• Adrenomedullin at the US National Library of Medicine Medical Subject Headings (MeSH)